Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Pelthos Therapeutics Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +3 vs. Q4 2025
- Shares held
- 912.3K
- +88.0K (+10.7%) vs. Q4 2025
- Total value
- $19.2M
- −$6.39M (−25.0%) vs. Q4 2025
- New holders
- 5
- 8 more added
- Sold out
- 2
- 2 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTHS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $37.4M |
| Q1 2026 | 17 | $19.2M |
| Q4 2025 | 15 | $27.9M |
| Q3 2025 | 14 | $13.0M |
| Q2 2025 | 5 | $187.3K |
| Q1 2025 | 9 | $846.2K |
| Q4 2024 | 4 | $16.0K |
| Q3 2024 | 5 | $59.6K |
| Q2 2024 | 5 | $290.3K |
| Q1 2024 | 1 | $659.9K |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Pelthos Therapeutics Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Murchinson Ltd. | 296,314 | $6.23M | 2.50% | +6,835+2.4% | Added |
| Ikarian Capital, LLC | 256,598 | $5.39M | 0.77% | +840+0.3% | Added |
| Vanguard Capital Management LLC | 93,093 | $1.96M | 0.00% | +93,093 | New |
| Boothbay Fund Management, LLC | 81,858 | $1.72M | 0.04% | +1,178+1.5% | Added |
| J. Goldman & Co LP | 50,415 | $1.06M | 0.05% | −27,591−35.4% | Reduced |
| Cantor Fitzgerald, L. P. | 41,423 | $870.3K | 0.03% | +6,433+18.4% | Added |
| Diadema Partners LP | 24,773 | $520.5K | 0.21% | −227−0.9% | Reduced |
| Knott David M Jr | 21,073 | $442.7K | 0.26% | +1,792+9.3% | Added |
| Geode Capital Management, LLC | 15,290 | $321.2K | 0.00% | +1,665+12.2% | Added |
| Pale Fire Capital SE | 12,919 | $271.4K | 0.02% | +4,819+59.5% | Added |
| Vanguard Fiduciary Trust Co | 9,817 | $206.3K | 0.00% | +9,817 | New |
| Persistent Asset Partners Ltd | 6,007 | $126.2K | 0.05% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 1,910 | $40.1K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 764 | $16.1K | 0.00% | +330+76.0% | Added |
| Farther Finance Advisors, LLC | 40 | $852 | 0.00% | +40 | New |
| Aspect Partners, LLC | 16 | $336 | 0.00% | +16 | New |
| Citigroup Inc | 1 | $21 | 0.00% | +1 | New |
| Millennium Management LLC | 0 | $0 | 0.00% | −11,057−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |